Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PD-L1 inhibitors

- PMLiVE

ADA: Merck launches registry for type 2 diabetes

Will collect information from 20,000 patients across four countries

- PMLiVE

ASCO: Merck’s anti-PD1 impresses in skin and lung cancer

Promising MK-3475 immunotherapy to be known as pembrolizumab

- PMLiVE

Interview: AstraZeneca’s Susan Galbraith

As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer

Bristol-Myers Squibb (BMS) building

BMS’ nivolumab gets breakthrough status

But shares fall on concerns over new trial data

- PMLiVE

Merck’s first-in-class Zontivity cleared in US

FDA approves the protease-activated receptor-1 antagonist to reduce heart attack risk

- PMLiVE

AZ starts pivotal trials of lung cancer immunotherapy

Moves MEDI4736 into phase III testing for non-small cell lung cancer

Novartis building

Novartis gets US nod for lung cancer relapse therapy Zykadia

Second ALK inhibitor to be approved after Pfizer’s Xalkori

Bristol-Myers Squibb (BMS) building

BMS buys Alzheimer’s player iPierian in $725m deal

Takes control of several promising candidates for neurodegenerative diseases

National Institute for Health and Care Excellence NICE logo

NICE backs two cancer drugs

Boehringer’s Giotrif and Janssen’s Velcade given final go-ahead for NHS use

- PMLiVE

Merck gets US green light for allergy immunotherapy

Expected to provide a significant boost to company's partner Alk-Abello

- PMLiVE

Oral hepatitis C regimens tackle advanced liver disease

 New data released at the International Liver Congress by AbbVie, Merck & Co and Gilead

Roche - Basel

NICE reverses decision to restrict Tarceva access

Roche says “voices of clinicians and patients have been heard”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links